{"transactions":[{"id":1943209,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":115317,"kind":"person","name":"Holdbrook Mark J.","position":1,"cik":"0001827564","reported_name":"Holdbrook Mark J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"V.P., Clinical Affairs"}}],"security":"Common Stock","published_at":"2023-03-21T23:06:38.000Z","date":"2023-03-20","kind":"sale","planned":false,"acquired":false,"shares":198,"price":12.61,"value":2496.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":3191,"source":{"system":"sec-edgar","filing":"0001827564-23-000002","document":"wf-form4_167943994647637.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000182756423000002/wf-form4_167943994647637.xml","form_type":"4"}},{"id":1943208,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":115317,"kind":"person","name":"Holdbrook Mark J.","position":1,"cik":"0001827564","reported_name":"Holdbrook Mark J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"V.P., Clinical Affairs"}}],"security":"Common Stock","published_at":"2023-03-21T23:06:38.000Z","date":"2023-03-17","kind":"sale","planned":false,"acquired":false,"shares":188,"price":13.28,"value":2496.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":3389,"source":{"system":"sec-edgar","filing":"0001827564-23-000002","document":"wf-form4_167943994647637.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000182756423000002/wf-form4_167943994647637.xml","form_type":"4"}},{"id":1947344,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":115317,"kind":"person","name":"Holdbrook Mark J.","position":1,"cik":"0001827564","reported_name":"Holdbrook Mark J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"V.P., Clinical Affairs"}}],"security":"Restricted Stock Units","published_at":"2023-03-17T22:22:23.000Z","date":"2023-03-15","kind":"exercise","acquired":false,"shares":2653,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan.  25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan.  25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service."}],"balance_after":7959,"derivative":{"underlying":"Common Stock","underlying_shares":2653},"source":{"system":"sec-edgar","filing":"0001209191-23-019885","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919123019885/doc4.xml","form_type":"4"}},{"id":1947343,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":115317,"kind":"person","name":"Holdbrook Mark J.","position":1,"cik":"0001827564","reported_name":"Holdbrook Mark J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"V.P., Clinical Affairs"}}],"security":"Common Stock","published_at":"2023-03-17T22:22:23.000Z","date":"2023-03-16","kind":"sale","acquired":false,"shares":187,"price":13.43,"value":2511.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":3577,"source":{"system":"sec-edgar","filing":"0001209191-23-019885","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919123019885/doc4.xml","form_type":"4"}},{"id":1947342,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":115317,"kind":"person","name":"Holdbrook Mark J.","position":1,"cik":"0001827564","reported_name":"Holdbrook Mark J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"V.P., Clinical Affairs"}}],"security":"Common Stock","published_at":"2023-03-17T22:22:23.000Z","date":"2023-03-15","kind":"exercise","acquired":true,"shares":2653,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to settlement of vested Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022."}],"balance_after":3764,"source":{"system":"sec-edgar","filing":"0001209191-23-019885","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919123019885/doc4.xml","form_type":"4"}},{"id":2337812,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":115317,"kind":"person","name":"Holdbrook Mark J.","position":1,"cik":"0001827564","reported_name":"Holdbrook Mark J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"V.P., Clinical Affairs"}}],"security":"Restricted Stock Units","published_at":"2022-03-11T21:13:34.000Z","date":"2022-03-09","kind":"grant","acquired":true,"shares":10612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service."}],"balance_after":10612,"derivative":{"underlying":"Common Stock","underlying_shares":10612},"source":{"system":"sec-edgar","filing":"0001827564-22-000002","document":"wf-form4_164703319575280.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000182756422000002/wf-form4_164703319575280.xml","form_type":"4"}},{"id":2337811,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":115317,"kind":"person","name":"Holdbrook Mark J.","position":1,"cik":"0001827564","reported_name":"Holdbrook Mark J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"V.P., Clinical Affairs"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T21:13:34.000Z","date":"2022-03-09","kind":"grant","acquired":true,"shares":36173,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option shares shall vest on March 9, 2023, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service."}],"balance_after":36173,"derivative":{"exercise_price":19.59,"expiration_date":"2032-03-08","underlying":"Common Stock","underlying_shares":36173},"source":{"system":"sec-edgar","filing":"0001827564-22-000002","document":"wf-form4_164703319575280.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000182756422000002/wf-form4_164703319575280.xml","form_type":"4"}},{"id":2809199,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":115317,"kind":"person","name":"Holdbrook Mark J.","position":1,"cik":"0001827564","reported_name":"Holdbrook Mark J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"V.P., Clinical Affairs"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-05T01:14:55.000Z","date":"2021-03-02","kind":"grant","acquired":true,"shares":14300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option granted under the Tarsus Pharmaceuticals, Inc. 2020 Equity Incentive Plan.  25% of the option shares shall vest and become exercisable on March 2, 2022, and 1/48th of the option shares shall vest and become exercisable each month thereafter for a period of 3 years."}],"balance_after":14300,"derivative":{"exercise_price":34.72,"expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":14300},"source":{"system":"sec-edgar","filing":"0001209191-21-018041","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919121018041/doc4.xml","form_type":"4"}}]}